ABSTRACT OBJECTIVE: Modifi cations in E-cadherin (E-Cad) expression are associated with dedifferentiation, progression, metastases and poor prognosis in many types of tumors. The aim of the present study was to identify a potential association of the pre-and post-operative soluble E-Cad levels (sE-Cad) with the clinicopathological parameters of patients with gastric cancer. PATIENTS AND METHODS: Serum sE-Cad levels were determined in 99 gastric cancer patients and 78 healthy volunteers using ELISA. RESULTS: Levels of sE-Cad were signifi cantly increased in gastric cancer patients compared with these levels in healthy controls (p < 0.001). For the evaluation of the diagnostic significance of sE-Cad the area under the receiver operating characteristic (ROC) curve (AUC) was 0.835, while the optimal cut-off point of 9.9 μg/mL was determined to classify gastric cancer patients, which yielded sensitivity of 72.7%, specifi city of 80.8% and accuracy of 76.3%. Poor differentiation (p = 0.009) and the presence of distant metastases (p < 0.001) were the two signifi cant independent prognostic determinants for high sE-Cad levels in multivariate linear regression analysis. The preoperative levels of sE-Cad also proved helpful in classifying patients according to the choice treatment (curative versus palliative) (AUC, 0.656); when the optimal cut-off point was set at 17.60 μg/mL, the sensitivity was 57%, the specifi city was 83% and accuracy was 75%. Survival was shorter in patients with increased sE-Cad (median, 7 months vs 39 months, p = 0.0002), although multivariate Cox regression analysis demonstrated a marginal prognostic signifi cance of sE-Cad for survival (adjusted HR = 1.68, 95% CI = 0.93 to 3.02, p = 0.072). CONCLUSIONS: Serum sE-Cad levels could be considered as a diagnostic and prognostic marker in gastric cancer patients as well as a tool to select a treatment approach. The prognostic value of sE-Cad on overall survival requires further study.
INTRODUCTION
Adhesion molecule E-cadherin (E-Cad) is implicated in pathological conditions such as abnormal morphogenesis, infl ammatory diseases, cancer invasion and metastases. [1] [2] [3] [4] Studies have identifi ed a soluble form of E-Cad (sE-Cad) in the serum of healthy individuals as well as cancer patients which is generated when the extracellular domain of E-Cad is cleaved by matrix metalloproteinases. [5] [6] [7] [8] sE-Cad levels are particularly high in patients with tumours of epithelial origin such as gastric cancer, suggesting a possible role of this molecule as a tumour marker of diagnostic and prognostic value. [9] [10] [11] [12] 
AIM
The aim of this study was to fi nd a possible association between pre-and post-operative sE-Cad levels with the clinicopathological parameters of patients with gastric carcinoma.
PATIENTS AND METHODS

STUDY POPULATION
The control group consisted of 78 healthy volunteers (median age ( ± SD): 66.50 ± 10.51 yrs; 55 males and 23 females). The absence of disease was confi rmed by clinical history, physical examination, and routine laboratory tests. Ninety-nine patients with newly diagnosed and histologically confi rmed gastric cancer were recruited for this study (median age ( ± SD): 68.04 ± 10.96 yrs; 74 males and 25 females). Patients who had received chemotherapy, radiotherapy or blood transfusion before surgery were excluded from the study. Staging was based on the TNM staging system for gastric cancer. 13 Tumors were histologically classifi ed as intestinal or diffuse according to their Lauren type 14 and were graded as well, moderately, or poorly differentiated based on the predominant cell type. Patients were followed prospectively and the date and cause of death was recorded. Median follow-up time was 44 months (range, 3 to 111 months).
Curative resection was defi ned as International Union Against Cancer R0 resection. Palliative treatment included International Union Against Cancer R1 or R2 resection, gastrojejunostomy, or palliative chemotherapy. Conservative treatment referred to treatment in which patients received symptomatic support only.
The regional ethics committee approved the project and written informed consent was obtained from all patients and controls before their inclusion in the study.
EVALUATION OF SE-CAD SERUM LEVELS Serum samples from gastric cancer patients were collected on admission and 30 days after surgery. sE-Cad levels were determined by a commercially available enzyme linked immunosorbent assay (Takara Bio Inc., Japan) according to the manufacturer's instructions.
STATISTICAL ANALYSIS Statistical analysis was performed by the SPSS, v. 19.0 (IBM). The normality of quantitative variables was tested with Kolmogorov-Smirnov test. sE-Cad levels were expressed as median values and interquartile ranges (IQR) and analyzed with nonparametric tests. Multivariate stepwise linear regression and ROC curve analysis were also performed. Survival rates were calculated with the Kaplan-Meier method and the statistical difference between survival curves was determined with the log-rank test. Multivariate Cox proportional hazards regression analysis using a backward selection approach, was also performed. All tests were two tailed and the level of statistical signifi cance was set at p < 0.05.
RESULTS
SE-CAD LEVELS IN HEALTHY SUBJECTS AND GASTRIC
CANCER PATIENTS sE-Cad was detectable in the serum of all control subjects with a median value of 7.00 μg/ml, IQR = 4.92 to 9.24 μg/ml. There was no signifi cant difference between males and females (p = 0.978), but there was a signifi cant positive correlation between sE-Cad and age (r = 0.246; p = 0.030).
sE-Cad was also detectable in all gastric cancer patients. Preoperative sE-Cad levels (median, 13.74 μg/ml, IQR = 8.81 to 19.19 μg/ml) were signifi cantly elevated when compared to healthy individuals (p < 0.001). There were no differences between males and females (p = 0.787) and no correlation was found between sE-Cad levels and patients' age (r = 0.104; p = 0.306).
VALIDITY OF SE-CAD AS A GASTRIC CANCER MARKER
According to ROC analysis, the area under the curve (AUC) was 0.835 (95% CI, 0.777 to 0.892; p < 0.001), suggesting that sE-Cad was a very good predictor of gastric cancer (Fig. 1) . The optimal cut-off point of 9.9 μg/mL, used to classify patients with gastric cancer, yielded high sensitivity (72.7%) 
ASSOCIATIONS BETWEEN SE-CAD AND CLINICOPATHOLOGIC
FEATURES
Associations between preoperative sE-Cad and clinicopathologic variables are shown in Table 1 . There was a signifi cant association between sE-Cad and tumor differentiation, with poorly differentiated tumors being associated with higher sE-Cad levels compared with well/moderately differentiated tumors (16.54 μg/ml (10.41 -23.78) versus 11.74 μg/ml (8.61 -14.57) respectively, p = 0.004). The association of sE-Cad levels with TNM stage did not reach statistical signifi cance (ANOVA, p = 0.165). However, further analysis using the MannWhitney U test revealed that patients with stage IV disease had higher sE-Cad levels when compared to all other patients (stages I-III) (15.73 μg/ ml (8.54-28.41) versus 13.13 μg/ml (8.86-16.74), respectively; p = 0.048). The relationship between sE-Cad and the invasion depth of the tumor was statistically signifi cant (p = 0.019), while further analysis demonstrated that patients with locally advanced (T4) tumors had signifi cantly higher sE-Cad levels compared to those with gastric wall-limited (T1-T3) tumors (18.67 μg/ml (10.70 -31.10) vs 13.23 μg/ml (8.46 -16.87) respectively, p = 0.013). Patients with distant metastases had signifi cantly higher sE-Cad levels compared to those without metastatic disease (p = 0.012).
According to multivariate stepwise linear regression analysis poor differentiation (regression coeffi cient = 4.257, SE = 1.593 P = 0.009, R 2 = 5.9%) and the presence of distant metastases (regression coeffi cient = 8.147, SE = 2.099, p < 0.001, R 2 = 15.1%) were the major signifi cant independent prognostic determinants for high sE-Cad levels.
EFFECT OF SURGERY ON SE-CAD LEVELS
The effect of surgical resection of the tumor on sECad was evaluated by determining their pre-operative The accuracy of preoperative sE-Cad concentrations to identify the type of surgery (radical versus palliative or unresectable disease) was evaluated by constructing the relevant ROC curve. The produced AUC was 0.656 (95%CI, 0.526-0.787, p = 0.014) and the optimal cut-off point was defi ned at 17.60 μg/mL showing sensitivity of 57.0% and specifi city of 83.0% with positive and negative predictive values of 59.0% and 81.4% respectively, and an overall diagnostic accuracy of 75.0% in predicting the choice treatment.
ASSOCIATIONS BETWEEN SE-CAD AND PATIENT SURVIVAL The 17.60 μg/mL cut off point defi ned as optimal in predicting the type of surgical resection was also used to assess sE-Cad-dependent overall survival. High sE-Cad levels were found in 29 patients (29.3%). During follow-up, 51 patients died from gastric cancer progression, 42 patients remained alive with no evidence of disease and 6 patients were lost to follow-up. Univariate analysis showed that radical resection, TNM stage, depth of gastric wall invasion, lymph node metastasis, distant metastasis, and elevated preoperative sE-Cad levels were signifi cant factors affecting overall survival (Table  2 ). In particular, mean survival time was 52 months (95% CI, 41 -64 months; median time, 39 months) in patients with low sE-Cad levels and 18 months (95% CI, 9 -27 months; median time, 7 months) in patients with high sE-Cad levels. Log-rank test revealed that high ( > 17.60 μg/ml) preoperative sE-Cad levels were signifi cantly associated with poor overall survival (p = 0.0002; Fig. 2 ). Mortality rate was signifi cantly greater in patients with high sE-Cad levels compared to patients with low sE-Cad levels (76.9% vs 46.3%, p = 0.008), where patients with high levels of sE-Cad were almost 3 times more likely to die of cancer than those with low levels of sE-Cad (HR = 2.79, 95% CI = 1.57 to 4.93, p = 0.0004). When other cut-off points for sE-Cad levels were selected, such as the 95 th percentile (13.13 μg/ml) of the control group, the 50 th (13.74 μg/ml) or 75 th (19.19 μg/ml) percentile of patients, similar results were obtained.
Further investigation with multivariate Cox proportional hazards regression analysis revealed that the independent impact of serum sE-Cad levels on overall survival was of borderline statistical signifi cance (HR = 1.68, 95% CI = 0.93 to 3.02, p = 0.071). Moreover, the depth of gastric wall invasion (HR = 4.97, 95% CI = 2.46 to 10.02, p < 0.001) and the presence of lymph nodes metastasis (HR = 2.26, 95% CI = 1.01 to 5.03, p = 0.046) remained signifi cant independent factors for poor cancer-specifi c survival in decreasing order of potency.
DISCUSSION
In the present study, we evaluated sE-Cad levels in healthy volunteers and in gastric cancer patients (pre-and post-operation). Age-matched populations were recruited in this particular study. Our results are in agreement with previous studies demonstrating that serum sE-Cad is signifi cantly elevated in gastric cancer patients. [9] [10] [11] [12] Moreover, preoperative sE-Cad levels higher than 9.9 μg/mL were proven a reliable diagnostic tool for gastric cancer. Unlike previous reports, preoperative sE-Cad was associ- High preoperative sE-Cad levels were associated with tumor invasion to adjacent structures (T4), while the presence of distant metastases and the tumor's poor differentiation were proven signifi cant independent prognostic determinants. Advanced tumor stage has been found to be associated with membrane bound E-Cad-immunonegative primary gastric carcinoma tumors and increased sE-Cad levels at the same time 15, 16 , while Chan et al. suggested that high sE-Cad levels might be correlated with the presence of micrometastasis 11 .
According to our results, preoperative sE-Cad levels signifi cantly decreased 30 days after radical resection of the tumor. The opposite was observed in patients that underwent a palliative bypass or a non-curative resection. These observations suggest that sE-Cad could be used to evaluate the surgical completeness but further studies are required.
Palliative treatment was the treatment of choice in patients with preoperative sE-Cad levels higher than 17.6 μg/ml. Chan et al. observed that palliative/conservatively treated patients had high sE-Cad levels that were correlated with the size of the tumor. 10 High preoperative sE-Cad levels were also associated with poor overall survival and increased mortality rate, with marginal prognostic signifi cance.
CONCLUSIONS
Serum sE-Cad could be considered as a diagnostic and prognostic marker in gastric cancer patients as well as a tool to identify the choice treatment. The prognostic value of sE-Cad on overall survival requires further study.
